| Outcome Measures: |
Primary: Proportion of participants who experienced 1 or more treatment-emergent AEs, After treatment with the combination of K-757 and K-833, Up to Day 42 +/- 2days|Proportion of participants who discontinued study medication due to an AE, After treatment with the combination of K-757 and K-833, Up to Day 42 +/- 2days | Secondary: Area under the concentration-time curve [AUC] of plasma K-757, when co-administered with K-833, Days 14 and 28|AUC of plasma K-833, when co-administered with K-757, Days 14 and 28|Maximum concentration [Cmax] of plasma K-757, when co-administered with K-833, Days 14 and 28|Cmax of plasma K-833, when co-administered with K-757, Days 14 and 28|Time of maximum concentration [Tmax] of plasma K-757, when co-administered with K-833, Days 14 and 28|Tmax of plasma K-833, when co-administered with K-757, Days 14 and 28|Clearance [Cl] of plasma K-757, when co-administered with K-833, Days 14 and 28|Cl of plasma K-833, when co-administered with K-757, Days 14 and 28|Volume of distribution at steady-state [Vdss] of plasma K-757, when co-administered with K-833, Days 14 and 28|Vdss of plasma K-833, when co-administered with K-757, Days 14 and 28|Half-life [t1/2] of plasma K-757, when co-administered with K-833, Days 14 and 28|t1/2 of plasma K-833, when co-administered with K-757, Days 14 and 28
|
